文献速递浆细胞疾病血栓与止血

新诊断多发性骨髓瘤患者接受RVD或KRD方案联合阿司匹林或利伐沙班血栓预防的静脉血栓栓塞发生率比较

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
PubMed 文献 · Br J Haematol · 2021-08-15

该回顾性研究纳入305例新诊断多发性骨髓瘤患者,比较KRD+阿司匹林、RVD+阿司匹林及KRD+利伐沙班三组的静脉血栓栓塞发生率。KRD诱导较RVD诱导的VTE发生率更高,低剂量利伐沙班血栓预防可降低该风险且未观察到出血率增加。

要点

  • 低剂量利伐沙班血栓预防未观察到出血率增加。

核心结论

  • KRD诱导较RVD诱导的新诊断多发性骨髓瘤患者VTE发生率更高。
  • 低剂量利伐沙班血栓预防可降低KRD诱导相关的VTE风险,且未观察到出血率增加。

研究设计与样本

  • 回顾性研究,纳入305例新诊断多发性骨髓瘤患者。
  • 比较KRD+阿司匹林、RVD+阿司匹林及KRD+利伐沙班三组的VTE发生率。

主要发现

  • 三组VTE发生率差异有统计学意义。

临床怎么用

  • 对于接受KRD诱导的新诊断多发性骨髓瘤患者,可考虑低剂量利伐沙班进行血栓预防以降低VTE风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Incidence of venous thromboembolism (VTE) varies across different regimens in newly diagnosed multiple myeloma (NDMM) patients. Limited data exist on the use of direct oral anticoagulants as thromboprophylaxis in the setting of haematologic malignancies, specifically multiple myeloma. In this retrospective study of 305 NDMM patients, VTE rates in those treated with carfilzomib, lenalidomide, dexamethasone (KRD) + aspirin (ASA), bortezomib, lenalidomide, dexamethasone (RVD) + ASA, and KRD + rivaroxaban were statistically significant, 16·1%, 4·8%, and 4·8%, respectively. The findings confirm a higher incidence of VTE when using KRD induction compared to RVD induction and reveal that the use of low-dose rivaroxaban thromboprophylaxis can mitigate this risk without an observable increase in bleeding rates.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Piedra K, Peterson T, Tan C, et al. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Br J Haematol. 2021. PMID: 34396516. doi:10.1111/bjh.17772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。